BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Thomas Bortfeld

Thomas Bortfeld contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
physics.med-ph

Trust snapshot

Quick read

Trust 19 - UnverifiedVerification L1Unclaimed author
5works
0followers
1topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

5 published item(s)

preprint2026arXiv

Bi-level Multi-criteria Optimization for Risk-informed Radiotherapy

In radiation therapy (RT) treatment planning, multi-criteria optimization (MCO) supports efficient plan selection but is usually solved for population-based dosimetric criteria and ignores patient-specific biological risk, potentially compromising outcomes in high-risk patients. We propose risk-guided MCO, a one-shot method that embeds a clinical risk model into conventional MCO, enabling interactive navigation between dosimetric and biological endpoints. The proposed algorithm uses a special order relation to fuse the classical MCO sandwiching algorithm with bi-level optimization, restricting the Pareto set to plans that achieve improvement in the secondary risk objective for user-defined, acceptable loss in primary clinical objectives. Thus, risk-guided MCO generates risk-optimized counterparts of clinical plans in a single run rather than by sequential or lexicographic planning. To assess the performance, we retrospectively analyzed 19 lung cancer patients treated with RT. The endpoint was the risk of grade 2+ radiation pneumonitis (RP), modeled using bootstrapped stepwise logistics regression with interaction terms, including baseline lung function, smoking history, and dosimetric factors. The risk-guided plans yielded a mean reduction of 8.0% in total lung V20 and 9.5% in right lung V5, translating into an average RP risk reduction of 7.7% (range=0.3%-20.1%), with small changes in target coverage (mean -1.2 D98[%] for CTV) and modest increase in heart dose (mean +1.74 Gy). This study presents the first proof-of-concept for integrating biological risk models directly within multi-criteria RT planning, enabling an interactive balance between established population-wide dose protocols and individualized outcome prediction. Our results demonstrate that the risk-informed MCO can reduce the risk of RP while maintaining target coverage.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Does the greater power of pencil beam scanning reduce the need for a proton gantry? A study of head-and-neck and brain tumors

Proton therapy systems without a gantry can be more compact and less expensive in terms of capital cost, and therefore more available to a larger patient population. Would the advances in pencil beam scanning and robotics make gantry-less treatment possible? In this study, we explore if high-quality treatment plans can be obtained without a gantry. We recently showed that proton treatments with the patient in an upright position may be feasible with a new soft robotic immobilization device and imaging which enables multiple possible patient orientations during a treatment. In this study, we evaluate if this new treatment geometry could enable high quality treatment plans without a gantry. We created pencil beam scanning (PBS) treatment plans for seven patients with head-and-neck or brain tumors. Each patient was planned with two scenarios: one with a gantry with the patient in supine position and the other with a gantry-less fixed horizontal beam-line with the patient sitting upright. For the treatment plans, dose-volume-histograms (DVHs), target homogeneity index (HI), mean dose, D_2 and D_98 are reported. A robustness analysis of one plan was performed with +/-2.5 mm setup errors and +/-3.5% range uncertainties with nine scenarios. Most of the PBS-gantry-less plans had similar target HI and OAR mean dose as compared to PBS-gantry plans, and similar robustness with respect to range uncertainties and setup errors. Pencil beam scanning provides sufficient power to deliver high quality treatment plans without requiring a gantry for head-and-neck or brain tumors. In combination with the development of the new positioning and immobilization methods required to support this treatment geometry, this work suggests the feasibility of further development of a compact proton therapy system with a fixed horizontal beam-line to treat patients in sitting and reclined positions.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging

Objective: Soft-tissue sarcoma spreads preferentially along muscle fibers. We explore the utility of deriving muscle fiber orientations from diffusion tensor MRI (DT-MRI) for defining the boundary of the clinical target volume in muscle tissue. Approach: We recruited eight healthy volunteers to acquire MR images of the left and right thigh. The imaging session consisted of (a) two MRI spin-echo-based scans, T1- and T2-weighted; (b) a diffusion weighted (DW) spin-echo-based scan using an echo planar acquisition with fat suppression. The thigh muscles were auto-segmented using CNN. DT-MRI data was used as a geometry encoding input to solve the anisotropic Eikonal equation with Hamiltonian Fast-Marching method. The isosurfaces of the solution modeled the CTV boundary. Main results: The auto-segmented muscles of the thigh agreed with manually delineated with the Dice score ranging from 0.8 to 0.94 for different muscles. Anisotropy of the isosurfaces was compared across muscles with different anatomical orientations within a thigh, between muscles in left and right thighs of each subject, and between different subjects. Analysis showed a high degree of consistency across all comparisons. The distance from the GTV to the isosurface and the eigenvalues ratio are two controlling parameters for the extent and shape of the CTV. Significance: Our feasibility study with healthy volunteers shows the promise of using muscle fiber orientations derived from diffusion weighted MRI data for automated generation of anisotropic CTV boundary in soft tissue sarcoma. Our contribution is significant as it is expected to lead to the improvements in the treatment outcomes of soft-tissue sarcoma patients undergoing radiotherapy and decrease amputation rate for a subset of patients. We expect such improvements to have a strong positive impact for the cancer centers with small volume of sarcoma patients.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Modeling the propagation of tumor fronts with shortest path and diffusion models -- implications for the definition of the clinical target volume

Objective: The overarching objective is to make the definition of the clinical target volume (CTV) in radiation oncology less subjective and more scientifically based. The specific objective of this study is to investigate similarities and differences between two methods that model tumor spread beyond the visible gross tumor volume (GTV): 1. The shortest path model, which is the standard method of adding a geometric GTV-CTV margin, and 2. The reaction-diffusion model. Approach: These two models to capture the invisible tumor "fire front" are defined and compared in mathematical terms. The models are applied to example cases that represent tumor spread in non-uniform and anisotropic media with anatomical barriers. Main Results: The two seemingly disparate models bring forth traveling waves that can be associated with the front of tumor growth outward from the GTV. The shape of the fronts is similar for both models. Differences are seen in cases where the diffusive flow is reduced due to anatomical barriers, and in complex spatially non-uniform cases. The diffusion model generally leads to smoother fronts. The smoothness can be controlled with a parameter defined by the ratio of the diffusion coefficient and the proliferation rate. Significance: Defining the CTV has been described as the weakest link of the radiotherapy chain. There are many similarities in the mathematical description and the behavior of the common geometric GTV-CTV expansion method, and the definition of the CTV tumor front via the reaction-diffusion model. Its mechanistic basis and the controllable smoothness make the diffusion model an attractive alternative to the standard GTV-CTV margin model.

0 citations0 reviewsNo code linkedOpen access
preprint2021arXiv

Adjustable robust treatment-length optimization in radiation therapy

Traditionally, optimization of radiation therapy (RT) treatment plans has been done before the initiation of RT course, using population-wide estimates for patients' response to therapy. However, recent technological advancements have enabled monitoring individual patient response during the RT course, in the form of biomarkers. Although biomarker data remains subject to substantial uncertainties, information extracted from this data may allow the RT plan to be adapted in a biologically informative way. We present a mathematical framework that optimally adapts the treatment-length of an RT plan based on the acquired mid-treatment biomarker information, while accounting for the inexact nature of this information. We formulate the adaptive treatment-length optimization problem as a 2-stage problem, wherein the information about the model parameters gathered during the first stage influences the decisions in the second stage. Using Adjustable Robust Optimization (ARO) techniques we derive explicit optimal decision rules for the stage-2 decisions and solve the optimization problem. The problem allows for multiple worst-case optimal solutions. To discriminate between these, we introduce the concept of Pareto Adjustable Robustly Optimal (PARO) solutions. In numerical experiments using lung cancer patient data, the ARO method is benchmarked against several other static and adaptive methods. In case of exact biomarker information, there is sufficient space to adapt, and numerical results show that taking into account both robustness and adaptability is not necessary. In case of inexact biomarker information, accounting for adaptability and inexactness of biomarker information is particularly beneficial when robustness (w.r.t. organ-at-risk (OAR) constraint violations) is of high importance. If minor OAR violations are allowed, a nominal folding horizon approach is a good performing alternative.

0 citations0 reviewsNo code linkedOpen access